Effect of metformin on clinical, metabolic and endocrine outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials

Current Medical Research and Opinion

Volumn 33, Issue 9, 2017, Pages 1545-1557

  Patel, Roshni ^a   Shah, Gaurang ^b  

^a K B INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH   (India)

^b L M COLLEGE OF PHARMACY   (India)

Author keywords

Clinical; endocrine; meta analysis; metabolic; metformin; polycystic ovary syndrome

Indexed keywords

ANDROGEN; CHOLESTEROL; ESTRADIOL; FOLLITROPIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; LUTEINIZING HORMONE; METFORMIN; PRASTERONE SULFATE; PROGESTERONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; ANTIDIABETIC AGENT;

BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL OUTCOME; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; ESTRADIOL BLOOD LEVEL; FERRIMAN GALLWAY SCORE; FOLLITROPIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INSULIN BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LUTEINIZING HORMONE BLOOD LEVEL; META ANALYSIS; METABOLISM; OVARY POLYCYSTIC DISEASE; PROGESTERONE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCORING SYSTEM; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST TO HEIGHT RATIO; BLOOD; FEMALE;

FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; HYPOGLYCEMIC AGENTS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LUTEINIZING HORMONE; METFORMIN; POLYCYSTIC OVARY SYNDROME; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE;

EID: 85027699560     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1080/03007995.2017.1279597     Document Type: Review

References (53)

1. Hart R, Hickey M, Franks S., Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pr Res Clin Obs Gynaecol 2004;18:671-83
2. Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-9
3. Pasquali R, Stener-Victorin E, Yildiz BO, et al. PCOS Forum:research in polycystic ovary syndrome today and tomorrow. Clin Endocrinol 2011;74:424-33
4. Guzick D, York N., Polycystic ovary syndrome:symptomatology, pathophysiology, and epidemiology. Am J Obs Gynecol 1998;179:89-93
5. Park KH, Kim JY, Ahn CW, et al. Polycystic ovarian syndrome (PCOS) and insulin resistance. Int J Gynaecol Obstet 2001;74:261-7
6. Ehrmann D, Barnes R, Rosenfield R, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141-6
7. Moran LJ, Misso ML, Wild RA, Norman RJ., Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome:a systematic review and meta-analysis. Hum Reprod Update 2010;16:347-63
8. Hoffman LK, Ehrmann DA., Cardiometabolic features of polycystic ovary syndrome. Nat Clin Pr Endocrinol Metab 2008;4:215-22
9. Teede H, Deeks A, Moran L., Polycystic ovary syndrome:a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 2010;8:41-50
10. Dunaif A., Insulin resistance and the polycystic ovary syndrome:mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800
11. Carmina E, Lobo RA., Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2004;82:661-5
12. Ovalle F, Azziz R., Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 2002;77:1095-105
13. Azziz R, Dumesic DA, Chazenbalk G, Goodarzi MO., Polycystic ovary syndrome:etiology, pathogenesis and diagnosis. Nat Rev Endocrinol 2011;7:219-31
14. Burt Solorzano CM, Beller JP, Abshire MY, et al. Neuroendocrine dysfunction in polycystic ovary syndrome. Steroids 2012;77:332-7
15. Kirpichnikov D, Mcfarlane S, Sowers J., Metformin:an update. Ann Intern Med 2002;137:25-33
16. Wright JJ, Tylee TS., Pharmacologic therapy of type 2 diabetes. Med Clin North Am 2016;100:647-63
17. Velazquez EM, Mendoza S, Hamer T, et al. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43:647-54
18. Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic clinical evaluation. J Clin Endocrinol Metab 2014;85:139-46
19. Glueck CJ, Wang P, Fontaine R, et al. Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). J Adolesc Heal 2001;29:160-9
20. Gao L, Zhao F, Li S., Statin is a reasonable treatment option for patients with polycystic ovary syndrome:a meta-analysis of randomized controlled trials. Exp Clin Endocrinol Diabetes 2012;120:367-75
21. Tang T, Lord J, Norman R, et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2012;5:1-160
22. Du Q, Wang Y-J, Yang S, et al. A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. Curr Med Res Opin 2012;28:723-30
23. Naderpoor N, Shorakae S, De Courten, B, et al. Metformin and lifestyle modification in polycystic ovary syndrome:systematic review and meta-analysis. Hum Reprod Updat 2015;21:1-15
24. Choi E, Yang Y., Efficacy and safety of metformin or oral contraceptives, or both in polycystic ovary syndrome. Ther Clin Risk Manag 2015;11:1345-53
25. Misso ML, Costello MF, Garrubba M, et al. Metformin versus clomiphene citrate for infertility in non-obese women with polycystic ovary syndrome:a systematic review and meta-analysis. Hum Reprod Update 2013;19:2-11
26. Cassina M, Dona M, Di, Gianantonio E, et al. First-trimester exposure to metformin and risk of birth defectsâ:a systematic review and meta-analysis. Hum Reprod Updat 2014;20:656-69
27. Feng L, Lin X, Wan Z, et al. Efficacy of metformin on pregnancy complications in women with polycystic ovary syndrome:a meta-analysis. Gynecol Endocrinol 2015;31:833-9
28. Zhuo Z, Wang A, Yu H., Effect of metformin intervention during pregnancy on the gestational diabetes mellitus in women with polycystic ovary syndrome:a systematic review and meta-analysis. J Diabetes Res 2014;1-13
29. Lord JM, Flight IHK, Norman RJ., Metformin in polycystic ovary syndrome:systematic review and meta-analysis. BMJ 2003;327:951-3
30. Nieuwenhuis-Ruifrok AE, Kuchenbecker WKH, Hoek A, et al. Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese:systematic review and meta-analysis. Hum Reprod Update 2009;15:57-68
31. Liberati A, Altman D, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions:explanation and elaboration. J Clin Epidemiol 2009;62:e1-34
32. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011
33. Önalan G, Goktolga U, Ceyhan T, et al. Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy:obese, lean, hyper or normoinsulinemic? Eur J Obstet Gynecol Reprod Biol 2005;123:204-11
34. Maciel GAR, Soares JM, Alves Da Motta EL, et al. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil Steril 2004;81:355-60
35. Baillargeon JP, Jakubowicz DJ, Iuorno MJ, et al. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004;82:893-902
36. Bonakdaran S, Khorasani ZM, Davachi B, Khorasani JM., The effects of calcitriol on improvement of insulin resistance, ovulation and comparison with metformin therapy in PCOS patients:a randomized placebo-controlled clinical trial. Iran J Reprod Med 2012;10:465-72
37. Chou K, Corleta H, Capp E, Spritzer P., Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome:a randomized, double-blind and placebo-controlled trial. Horm Metab Res 2003;35:86-91
38. Eisenhardt S, Schwarzmann N, Henschel V, et al. Early effects of metformin in women with polycystic ovary syndrome:a prospective randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2006;91:946-52
39. Hoeger KM, Kochman L, Wixom N, et al. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome:a pilot study. Fertil Steril 2004;82:421-9
40. Hoeger K, Davidson K, Kochman L, et al. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab 2008;93:4299-306
41. Palomba S, Falbo A, Russo T, et al. Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:3128-35
42. Guido M, Romualdi D, Giuliani M, et al. Effect of metformin on the growth hormone response to growth hormone-releasing hormone in obese women with polycystic ovary syndrome. Fertil Steril 2005;84:1470-6
43. Romualdi D, Giuliani M, Cristello F, et al. Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome:a randomized double-blind placebo-controlled clinical trial. Fertil Steril 2010;93:2303-10
44. Kelly CJG, Gordon D., The effect of metformin on hirsutism in polycystic ovary syndrome. Eur J Endocrinol 2002;147:217-21
45. Lord J, Thomas R, Fox B, Acharya U, Wilkin T. The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome–a randomised, double-blind, placebo-controlled trial. BJOG 2006;113:817-24
46. Trolle B, Flyvbjerg A, Kesmodel U, Lauszus FF., Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome:a randomized, double-blinded, placebo-controlled cross-over trial. Hum Reprod 2007;22:2967-73
47. Trolle B, Lauszus F, Frystyk J, et al. Adiponectin levels in women with polycystic ovary syndrome:impact of metformin treatment in a randomized controlled study. Fertil Steril 2010;94:2234-8
48. Costello MF, Eden JA., A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril 2003;79:1-13
49. Lord JM, Flight IHK, Norman RJ., Metformin in polycystic ovary syndrome:systematic review. Br Med J 2003;327:1-6
50. Ferriman D, Gallwey JD. Clinical Assessment of Body Hair. J Clin Endocrinol Metab 1961;21:1440-7
51. Aubuchon M, Lieman H, Stein D, et al. Metformin does not improve the reproductive or metabolic profile in women with polycystic ovary syndrome (PCOS). Reprod Sci 2009;16:938-46
52. Agarwal N, Rice SPL, Bolusani H, Luzio SD, Dunseath G, Ludgate M, et al. Metformin Reduces Arterial Stiffness and Improves Endothelial Function in Young Women with polycystic ovary syndrome:a randomized, placebo-controlled, crossover trial. J Clin Endocrinol Metab 2015;95:722-30
53. Fleming R, Wallace AM, Greer IA, Sattar NHZE., Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab 2002;87:569